Antares Pharma (AMEX:AIS), a specialty pharmaceutical company focused on improved alternatives to traditional drug delivery, today announced that Jack E. Stover, President & Chief Executive Officer, is scheduled to present a corporate overview at BIO CEO & Investor Conference at the Waldorf=Astoria Hotel in New York City.
The Company’s presentation will take place at 9:30 a.m. (Eastern) on Tuesday, February 12, 2008. There will be a live webcast of the presentation, which will be accessible through a link posted on the Antares website investor relations section. The webcast will be available for replay on Antares’ website through January 2009.
About Antares Pharma
Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has three validated drug delivery platforms: the ATDTM Advanced Transdermal Delivery system, subcutaneous injection technology platforms including both VibexTM disposable mini-needle injection device and ValeoTM/Vision® reusable needle-free injection devices; and Easy TecTM oral fast-melt technology. Two of the platforms have generated FDA approved products. Antares Pharma leverages its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. The Company’s products are engineered to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.